Publications by authors named "L Zitvogel"
Over the last decade, the annual Immunorad Conference, held under the joint auspicies of Gustave Roussy (Villejuif, France) and the Weill Cornell Medical College (New-York, USA) has aimed at exploring the latest advancements in the fields of tumor immunology and radiotherapy-immunotherapy combinations for the treatment of cancer. Gathering medical oncologists, radiation oncologists, physicians and researchers with esteemed expertise in these fields, the Immunorad Conference bridges the gap between preclinical outcomes and clinical opportunities. Thus, it paves a promising way toward optimizing radiotherapy-immunotherapy combinations and, from a broader perspective, improving therapeutic strategies for patients with cancer.
View Article and Find Full Text PDFArticle Synopsis
- The danger theory of immunity, proposed by Polly Matzinger in 1994, highlights that tissue damage or stress significantly influences immune responses, emphasizing the roles of antigenicity and adjuvanticity.
- Recent research supports the theory by examining various molecular patterns and stress-related signals that activate the immune system, especially in contexts like cancer and infections.
- The discussion includes how pathogens can evade immune detection and how conditions like intestinal dysbiosis undermine immune function, along with hereditary factors that validate the danger theory and its relationship with immune tolerance mechanisms.
Article Synopsis
- The study investigated the significance of metabolic tumor volume (tMTV) in patients with advanced non-small cell lung cancer (NSCLC) undergoing immune checkpoint blockade (ICB) therapy, using 18F-FDG-PET/CT scans.
- It involved 518 patients across multiple institutions and found that those with high tMTV had poorer overall survival when treated with ICBs alone compared to those with low tMTV.
- The research suggests that high tMTV is associated with increased systemic inflammation and genomic instability, making it a potential biomarker for determining treatment strategies in NSCLC patients with positive PD-L1 expression.
Article Synopsis
- * Recent studies show that blocking ACBP can make cancer treatments work better, but giving diazepam can cancel out those benefits.
- * Benzodiazepines like diazepam might weaken the immune response during cancer treatments, which needs more research to understand fully.